High Purity and Quality: Manufactured under strict quality controls to ensure optimal efficacy and reliability
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
For many, they reduce hunger and constant food thoughts
Ascendis could receive up to $285 million in total payments for this leading drug program, covering upfront fees, development, and regulatory milestones
BPC-157 Heal Faster
Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot